App-Quantinova.ai

Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)

Nicholas Turner - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial

Belinda Kingston - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

Ivana Sestak - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Ten year results of the international breast cancer intervention study II

Jack Cuzick - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Anastrozole

MONARCH E: A phase 3 study of standard adjuvant endocrine therapy with or without abemaciclib in patients with high risk, node positive, hormone-receptor positive, human epidermal growth factor receptor 2-negative early-stage breast cancer

Priya Rastogi - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Abemaciclib

A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2)

Nick C. Turner - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

TAS120

Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)

Peter Schmid - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Paclitaxel

Double PIK3CA mutations in cis drive oncogene addiction and enhance sensitivity to PI3K alpha inhibitors in breast cancer

Neil Vasan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Alpelisib

Developing a robust multidimensional molecular, pathological and radiological prognostic index (MPRPI) to evaluate the response to neoadjuvant chemotherapy (NACT) and predict clinical outcome of breast cancer (BC)

Tarek M. a. Abdel-Fatah - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Correlation between and molecular drivers of oncotype DX, prosigna, EndoPredict and breast cancer index: A TransATAC study

Richard Buus - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Anastrozole

MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors

Patrick Neven - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Abemaciclib

The relevance of internal mammary lymph nodes found during autologous breast reconstruction

Pooja Padmanabhan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Correlation of prognostic indicators based on clinical and pathological features in hormone receptor positive and HER2 receptor negative early breast cancer with the 21 gene assay recurrence score

Marianne Dillon - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

PITX2 DNA methylation: A prognostic/predictive biomarker for anthracycline-based chemotherapy

Marion Kiechle - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

Jos Manuel Prez-Garca - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Pembrolizumab

Preliminary safety data from stage 1 and 2 of the phase II/III PARTNER trial: Addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients

Karen Pinilla Alba - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Carboplatin

Therapeutic targeting of HOX gene dysregulation in triple negative breast cancer

Einthavy Arunachalam - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

CREBBP alterations lead to CDK4/6 inhibitor sensitivity in triple negative breast cancer

Rachael Natrajan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

ARISTACAT - Aromatase inhibition plus minus saracatinib as advanced breast cancer therapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

David Cameron - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

saracatinib

Sara M Tolaney - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Abemaciclib

Filters

45280 Abstracts